Most-Upgraded StocksMost-UpgradedNASDAQ:REGN Regeneron Pharmaceuticals (REGN) Stock Price, News & Analysis $1,184.93 -0.41 (-0.03%) (As of 11:08 AM ET) Add Compare Share Share Today's Range$1,180.00▼$1,189.7050-Day Range$1,024.09▼$1,196.8852-Week Range$769.19▼$1,203.49Volume27,264 shsAverage Volume469,685 shsMarket Capitalization$130.63 billionP/E Ratio35.01Dividend YieldN/APrice Target$1,104.65 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Regeneron Pharmaceuticals alerts: Email Address Regeneron Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.81 Rating ScoreUpside/Downside6.7% Downside$1,104.65 Price TargetShort InterestBearish1.82% of Shares Sold ShortDividend StrengthN/ASustainability-2.69Upright™ Environmental ScoreNews Sentiment0.44Based on 21 Articles This WeekInsider TradingSelling Shares$18.23 M Sold Last QuarterProj. Earnings Growth7.33%From $37.80 to $40.57 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.85 out of 5 starsMedical Sector216th out of 924 stocksPharmaceutical Preparations Industry85th out of 426 stocks 2.4 Analyst's Opinion Consensus RatingRegeneron Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.81, and is based on 16 buy ratings, 3 hold ratings, and 1 sell rating.Amount of Analyst CoverageRegeneron Pharmaceuticals has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Regeneron Pharmaceuticals' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted1.82% of the outstanding shares of Regeneron Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverRegeneron Pharmaceuticals has a short interest ratio ("days to cover") of 4.6.Change versus previous monthShort interest in Regeneron Pharmaceuticals has recently increased by 6.35%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldRegeneron Pharmaceuticals does not currently pay a dividend.Dividend GrowthRegeneron Pharmaceuticals does not have a long track record of dividend growth. Previous Next 2.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreRegeneron Pharmaceuticals has received a 8.96% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Aflibercept", "Casirivimab and imdevimab", and "Alirocumab" products. See details.Environmental SustainabilityThe Environmental Impact score for Regeneron Pharmaceuticals is -2.69. Previous Next 3.0 News and Social Media Coverage News SentimentRegeneron Pharmaceuticals has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 21 news articles for Regeneron Pharmaceuticals this week, compared to 15 articles on an average week.Search Interest17 people have searched for REGN on MarketBeat in the last 30 days. This is an increase of 6% compared to the previous 30 days.MarketBeat Follows25 people have added Regeneron Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 127% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Regeneron Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $18,230,142.00 in company stock.Percentage Held by InsidersOnly 7.48% of the stock of Regeneron Pharmaceuticals is held by insiders.Percentage Held by Institutions83.31% of the stock of Regeneron Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Regeneron Pharmaceuticals' insider trading history. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Regeneron Pharmaceuticals are expected to grow by 7.33% in the coming year, from $37.80 to $40.57 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Regeneron Pharmaceuticals is 34.98, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 145.04.Price to Earnings Ratio vs. SectorThe P/E ratio of Regeneron Pharmaceuticals is 34.98, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 139.34.Price to Earnings Growth RatioRegeneron Pharmaceuticals has a PEG Ratio of 3.12. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioRegeneron Pharmaceuticals has a P/B Ratio of 5.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Regeneron Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchFamous Stock Market Bull Issues Rare “Collapse” WarningTilson says we're in the midst of a collapse – unlike any we've seen since 2008. As you'll see, it all centers around the tech sector. And the epicenter – it turns out – is Apple.To watch his fascinating interview which has taken Wall Street by storm, click here. About Regeneron Pharmaceuticals Stock (NASDAQ:REGN)Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.Read More REGN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart REGN Stock News HeadlinesAugust 8, 2024 | insidertrades.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) VP Jason Pitofsky Sells 487 SharesAugust 21 at 9:54 PM | uk.finance.yahoo.comREGENERON PHARMACEUTICALS (1REGN.MI)August 22, 2024 | Crypto 101 Media (Ad)Massive Crypto Selloff = Historic OpportunityStocks recently suffered the worst 1-day loss since 2022… Cryptos got hammered as well…But here's the fact everyone is missing… As of this writing, Bitcoin is still up 28% year to date…And it's up 84% in the last year. August 21 at 9:54 PM | markets.businessinsider.comFDA Issues Complete Response Letter For Regeneron's Linvoseltamab In R/R Multiple MyelomaAugust 21 at 9:54 PM | msn.comRegeneron receives anticipated FDA rejection for blood cancer therapyAugust 21 at 11:11 AM | americanbankingnews.comRegeneron Pharmaceuticals (NASDAQ:REGN) Reaches New 12-Month High at $1,202.60August 20 at 7:17 PM | reuters.comUS FDA declines to approve Regeneron's blood cancer therapyAugust 20 at 6:45 PM | globenewswire.comRegeneron Provides Update on Biologics License Application for LinvoseltamabAugust 22, 2024 | Crypto 101 Media (Ad)Massive Crypto Selloff = Historic OpportunityStocks recently suffered the worst 1-day loss since 2022… Cryptos got hammered as well…But here's the fact everyone is missing… As of this writing, Bitcoin is still up 28% year to date…And it's up 84% in the last year. August 19 at 3:24 AM | americanbankingnews.comRegeneron Pharmaceuticals (NASDAQ:REGN) Cut to Buy at StockNews.comAugust 19 at 2:41 AM | americanbankingnews.comRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives $1,097.05 Consensus Target Price from BrokeragesAugust 18, 2024 | finance.yahoo.comREGN Aug 2024 960.000 put (REGN240823P00960000)August 17, 2024 | finance.yahoo.comRegeneron Pharmaceuticals' (NASDAQ:REGN) five-year earnings growth trails the incredible shareholder returnsAugust 17, 2024 | americanbankingnews.comRegeneron Pharmaceuticals (NASDAQ:REGN) Hits New 12-Month High at $1,165.95August 16, 2024 | ca.finance.yahoo.comREGN Aug 2024 975.000 callAugust 13, 2024 | investorplace.com3 Biotech Stocks Poised for a Comeback After Last Week's Market MeltdownAugust 13, 2024 | marketwatch.comRegeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitorsAugust 12, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: United Therapeutics (UTHR), Waters (WAT) and Regeneron (REGN)See More Headlines Receive REGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/01/2024Today8/22/2024Next Earnings (Estimated)11/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:REGN CUSIP75886F10 CIK872589 Webwww.regeneron.com Phone(914) 847-7000Fax914-347-2113Employees13,450Year Founded1988Price Target and Rating Average Stock Price Target$1,104.65 High Stock Price Target$1,300.00 Low Stock Price Target$720.00 Potential Upside/Downside-6.7%Consensus RatingModerate Buy Rating Score (0-4)2.81 Research Coverage21 Analysts Profitability EPS (Most Recent Fiscal Year)$33.85 Trailing P/E Ratio34.98 Forward P/E Ratio31.33 P/E Growth3.12Net Income$3.95 billion Net Margins32.04% Pretax Margin34.01% Return on Equity16.80% Return on Assets13.13% Debt Debt-to-Equity Ratio0.10 Current Ratio5.44 Quick Ratio4.62 Sales & Book Value Annual Sales$13.12 billion Price / Sales9.95 Cash Flow$43.44 per share Price / Cash Flow27.26 Book Value$236.63 per share Price / Book5.00Miscellaneous Outstanding Shares110,240,000Free Float101,944,000Market Cap$130.55 billion OptionableOptionable Beta0.13 Social Links 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesDr. Leonard S. Schleifer M.D. (Age 71)Ph.D., Co-Founder, President, CEO & Co-Chairman Comp: $8.18MDr. George D. Yancopoulos M.D. (Age 64)Ph.D., Co-Founder, President, Chief Scientific Officer & Co-Chairman Comp: $7.76MDr. Andrew J. Murphy Ph.D. (Age 65)Executive Vice President of Research Comp: $1.68MMr. Daniel P. Van Plew (Age 51)Executive VP and GM of Industrial Operations & Product Supply Comp: $2.01MMr. Christopher R. Fenimore CPA (Age 53)Senior VP of Finance & CFO Ms. Patrice GiloolySenior Vice President of Quality Assurance & OperationsMr. Bob McCowanSenior VP of IT & Chief Information OfficerMr. Ryan CroweSenior Vice President of Investor Relations & Strategic AnalysisMr. Joseph J. LaRosa (Age 65)Executive VP, General Counsel & Secretary Comp: $1.75MMs. Melissa LoznerSenior VP & Chief Compliance OfficerMore ExecutivesKey CompetitorsAmgenNASDAQ:AMGNVertex PharmaceuticalsNASDAQ:VRTXGilead SciencesNASDAQ:GILDAllerganNYSE:AGNAlexion PharmaceuticalsNASDAQ:ALXNView All CompetitorsInsiders & Institutions3Chopt Investment Partners LLCBought 538 shares on 8/22/2024Ownership: 0.000%Truist Financial CorpSold 1,630 shares on 8/21/2024Ownership: 0.037%Heartland Bank & Trust CoSold 286 shares on 8/21/2024Ownership: 0.001%EP Wealth Advisors LLCSold 17 shares on 8/19/2024Ownership: 0.001%Kimelman & Baird LLCBought 54 shares on 8/19/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions Should I Buy Regeneron Pharmaceuticals Stock? REGN Pros and Cons Explained Pros Here are some ways that investors could benefit from investing in Regeneron Pharmaceuticals, Inc.: Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema. Cons Investors should be bearish about investing in Regeneron Pharmaceuticals, Inc. for these reasons: One reason should include the current stock price. These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, July 29, 2024. Please send any questions or comments about these Regeneron Pharmaceuticals pros and cons to contact@marketbeat.com. REGN Stock Analysis - Frequently Asked Questions How have REGN shares performed this year? Regeneron Pharmaceuticals' stock was trading at $878.29 on January 1st, 2024. Since then, REGN stock has increased by 34.8% and is now trading at $1,184.23. View the best growth stocks for 2024 here. How were Regeneron Pharmaceuticals' earnings last quarter? Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced its earnings results on Thursday, August, 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, topping analysts' consensus estimates of $8.93 by $2.63. The company's revenue for the quarter was up 12.3% compared to the same quarter last year. Read the conference call transcript. What is Leonard S. Schleifer's approval rating as Regeneron Pharmaceuticals' CEO? 423 employees have rated Regeneron Pharmaceuticals Chief Executive Officer Leonard S. Schleifer on Glassdoor.com. Leonard S. Schleifer has an approval rating of 87% among the company's employees. Does Regeneron Pharmaceuticals have any subsidiaries? Regeneron Pharmaceuticals subsidiaries include these companies: Eastside Campus Holdings LLC, Loop Road Holdings LLC, Old Saw Mill Holdings LLC, OSMR Holdings, Regeneron Assurance Inc., Regeneron Atlantic Holdings, Regeneron Belgium BV, and more. Who are Regeneron Pharmaceuticals' major shareholders? Regeneron Pharmaceuticals' top institutional investors include Legal & General Group Plc (0.89%), Bank of New York Mellon Corp (0.78%), American Century Companies Inc. (0.75%) and Dimensional Fund Advisors LP (0.53%). Insiders that own company stock include George Yancopoulos, Leonard S Schleifer, Neil Stahl, Andrew J Murphy, Joseph J Larosa, Robert E Landry, Plew Daniel P Van, Arthur F Ryan, Christopher R Fenimore, Marion Mccourt, Joseph L Goldstein, Jason Pitofsky, Marc Tessier-Lavigne, Christine A Poon, Michael S Brown, Bonnie L Bassler, Huda Y Zoghbi, N Anthony Coles and George L Sing. View institutional ownership trends. How do I buy shares of Regeneron Pharmaceuticals? Shares of REGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Regeneron Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Regeneron Pharmaceuticals investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ) and Walt Disney (DIS). This page (NASDAQ:REGN) was last updated on 8/22/2024 by MarketBeat.com Staff From Our PartnersWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredMillionaire Investor Warns: “Brace for Apple Collapse”Apple stock has quadrupled over the past five years. But now even Warren Buffett is pulling the plug. The O...Stansberry Research | SponsoredMassive Crypto Selloff = Historic OpportunityStocks recently suffered the worst 1-day loss since 2022… Cryptos got hammered as well…But here's the fact ...Crypto 101 Media | SponsoredTrump is sounding the alarmEurope is one of the latest to release a central bank digital currency and along with it, new cash rules. Chri...Preserve Gold | SponsoredAir Force quietly working with sub $10 stock on new techThere is a little-known energy technology stock that has made an incredible breakthrough… Which could becom...DTI | SponsoredUS developing “superweapon” to defeat China and Russia?Our new superweapon is a gift to every patriot. I predict the devastating new tech behind this weapon will cre...Paradigm Press | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Regeneron Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Regeneron Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
